HK Stock Market Move | Biocytogen Pharmaceuticals-B(02315) rises by more than 5%, main business prosperity drives high income growth, institutions are optimistic about the company's long-term growth potential.

Biocytogen Pharmaceuticals-B (02315) surged more than 5%, reaching 5.41% as of press time, with a price of 47.96 Hong Kong dollars and a trading volume of 69.86 million Hong Kong dollars. On the news front, Biocytogen Pharmaceuticals recently released a forecast for its 2025 annual performance, estimating a revenue of approximately 1.369 billion to 1.389 billion yuan for the year, an increase of 389 million to 408 million yuan compared to the same period last year, with a year-on-year growth rate of 39.61% to 41.65%; it is also expected to achieve a net profit attributable to shareholders of approximately 162 million to 182 million yuan, an increase of 129 million to 149 million yuan compared to the same period last year, with a significant year-on-year growth of 384.26% to 443.88%. Guolian Minsheng Securities believes that the prosperous innovation of animal models and preclinical CRO business will drive high revenue growth. The company has reached external authorization agreements with several top domestic and foreign pharmaceutical companies since 2025, and multiple pipelines have obtained IND approvals. With the progress of authorized pipelines, the company is expected to receive milestone payments and other income, further opening up growth opportunities.